Posted by Michael Wonder on 13 Sep 2022
CStone announces China’s NMPA has accepted and granted priority review to the supplemental new drug application for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
13 September 2022 - GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.
CStone Pharmaceuticals today announced that the NMPA of China has accepted and granted priority review to the supplemental new drug application for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.
